EDO Pharmaceuticals

The requested name "EDO Pharmaceuticals" appears to refer to Endo, a life sciences company formerly operating as Endo, Inc. / Endo International plc rather than a standalone company literally named EDO Pharmaceuticals. Endo was a diversified specialty pharmaceutical company with commercial businesses spanning branded pharmaceuticals, generic pharmaceuticals, and sterile injectables, with key marketed products including XIAFLEX, AVEED, SUPPRELIN LA, VASOSTRICT, and ADRENALIN. In 2025, Endo completed a merger with Mallinckrodt, after which the combined companies separated the generics and sterile injectables business as Par Health and rebranded the specialty therapeutics business as Keenova Therapeutics. As a result, Endo no longer operates as an independent active company name, but it remains a relevant historical operating business and brand within the transaction history. For biotech analysts, the key takeaway is that this was a commercial-stage specialty pharma company with meaningful U.S. branded and hospital products rather than an early-stage R&D biotech.